Abstract
Introduction: it aimed to explore effectiveness and security of the hybrid artificial liver support system (HALSS) for chronic liver failure (CLF) patients, and analyze inflammatory response and prognosis of patients.
Material and Method: 126 patients with CLF divided into plasma exchange group (PEG), double plasma molecular absorb system group (DPMASG), and combination group (CG). Liver and kidney function, blood coagulation function, and T lymphocyte subgroup level change were compared, analysis of short-term clinical curative effect and adverse reactions after treatment.
Result: as against PEG and DPMASG, in CG, peripheral blood alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBil), total biliary acid, creatinine (Cr),international normalized ratio (INR), prothrombin time (PT) dropped and cholinesterase (ChE), albumin, prothrombin time activity (PTA) rose; peripheral blood CD4+ rose, CD8+ dropped, and inflammatory cytokine TNF-α, procalcitonin (PCT), interferon gamma (IFN-γ), IL-2, IL-6, and IL-10 levels were lower; model for end-stage liver disease (MELD) and Child-Turcotte-Pugh (CTP) score were lower (all P < 0.05). In PEG, DPMASG, and CG, the clinical total effective rate was 76.3%, 78.9%, and 92.0%, respectively; the adverse reaction rate (ARR) was 18.4%, 13.2%, and 8.0%; 1-year overall survival rate (SR) for follow-up was 18.4%, 21.1%, and 36.0%. CG had higher clinical effectiveness and 1-year overall survival, and lower rate of adverse reaction (P < 0.05).
Conclusion: PE+DPMAS can effectively improve the CLF, liver and kidney function, and blood coagulation function in patients.
Keywords
References
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.